English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Obesity is highly prevalent in polycystic ovary syndrome (PCOS). It aggravates adverse features of the syndrome. Weight management by lifestyle intervention is often insufficient. We reviewed studies addressing the use of agents mediating through incretin system in obese PCOS. Material and methods: Available relevant clinical trials were searched from PubMed. Results: Intervention with glucagon-like peptide 1 (GLP-1) analogue liraglutide is associated with consistent body mass index (BMI) reduction in treatment-naive obese women with PCOS and in poor responders to metformin and lifestyle modification. We recognized metformin as a well-suited combination with liraglutide. We demonstrated that liraglutide could also improve eating behavior and fertility potential in obese PCOS. Furthermore, we challenged the potential association of variability of GLP-1 receptor genotype and interindividual differences in response to liraglutide. In addition, we introduced the original concept related to the enhancement of incretin axis through phosphodiesterase 4 (PDE4). Nevertheless, we considered dipeptidyl peptidase 4 inhibitors as an alternative pharmacological intervention in metformin intolerant patients with PCOS. Conclusion: Agents mediating through incretin system in combination with lifestyle intervention and metformin could improve treatment outcomes in obese PCOS patients. Further studies are needed to establish the benefit/risk profile achieved by these potential new treatment strategies.

Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome